杨先达杨先达课题组目前有助理研究员一名，主任技师一名，研究生和进修生多名；有两个主要的科研方向：纳米技术的医学应用和肿瘤靶向分子的开发研究。
杨先达教授为协和医科大学医学博士、美国纽约州立大学理学博士和美国内科医师，既往曾任美国斯坦福大学博士后研究员、美国罗氏药厂科学家、美国法玛西药厂亚洲区医学总监、美国硅谷圣何西医学中心主治医师等职，具备基础科研、临床研究和临床医疗方面的丰富经验。在基础科研方面，成果曾发表于自然杂志(Nature)等国际学术刊物；在临床研究方面，曾设计和参与多项呈交美国FDA审批的国际性临床药物试验；在临床医疗方面，具美国行医执照和多年临床经验。回国后将碳纳米技术应用于抗肿瘤免疫疗法并取得了国际领先的科研成果，在肿瘤靶向分子的研发方面也有扎实的进展。
近年发表论文：
[1] Sun Zhao,Liu Zhe, Meng Jie, Meng Jie,DuanJinhong,Xie Sishen,Lu Xin,Zhu Zhaohui,Wang Chen,Shuchang,Xu Haiyan,Yang Xian-Da
Carbon Nanotubes Enhance Cytotoxicity Mediated by Human Lymphocytes
In Vitro(2011) Plosone, 6(6), pp 21073-21081

[2] Chenchen Yu,Yan Hu,Jinhong Duan, Xianda Yang
Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of
Anticancer Drug to MUC1-Positive Cancer Cells In Vitro(2011) Plosone,
6(9), pp 24077-24085

[3]Liu Zhe,Jinhong Duan,YongMei Song,Jie Ma,Fengda Wang,Xin Lu, Xian-DaYang
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug toHER2-positive Breast Cancer Cells in Vitro.J Transl Med, (2012) Jul 20; 10, 148-158

[4] Yan Hu, Jinhong Duan, QiminZhan,FengDan Wang,Xin Lu, Xian-Da Yang
Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer
cells in vitro.Plosone (2012)7（2）31970-31980

[5] Liang Zhang, Sun Zhao,Jinhong Duan,NingGu,Haiyan Xu,Xian-da Yang
Enhancement of DC-mediated anti-leukemic immunity in vitro by WT1
antigen and CpG co-encapsulated in PLGA microparticles Protein &
Cell, (2013)13(3916), pp1-3,

[6] Beibei Cao, Yan Hu, Jinhong Duan, JieMa, Danke Xu, Xian-Da Yang
Selection of a Novel DNA Aptamer for Assay of Intracellular
Interferon-Gamma (2014) PLoSONE 9(5): e98214.

[7] Wei Wang, Zhongjun Li, Jinhong Duan,Chen Wang, Ying Fang, and Xian-Da Yang
In vitro enhancement of dendritic cell-mediated anti-glioma immune
response by graphene oxide Nanoscale Research Letters （2014）, 9:311

[8] Lianyuan Yu, Yan Hu, Jinhong Duan, and Xian-Da Yang
A Novel Approach of TargetedImmunotherapy against Adenocarcinoma Cells
with Nanoparticles Modifiedby CD16 and MUC1 Aptamers（2015）
Journal of Nanomaterials ( Article ID 316968 p1-10 Hindawi PublishingCorporation)

[9]Hu Yan，J Duan，B Cao，L Zhang，X Lu，Xian-Da Yang
Selection of a Novel DNA Thioaptamer against HER2 Structure
Clinical & translational oncology (2015), 17(8):págs. 647-656

[10]GuoFangqin，Y Hu，L Yu，X Deng，J Meng，Xian-Da Yang
Enhancement of Thermal Damage to AdenocarcinomaCells by Iron
Nanoparticles Modified with MUC1 Aptamer
Joural of Nanoscience and nanotechnology (2016)，16(3):2246-2253

[11] Dai Bindong Hu yan Duan Jinhong, Yang xianda
Aptamer-guided DNA tetrahedron as a novel targeted drug deliverysystem
for muc1-expressing breast cancer cells in vitro Oncotarget (2016) Jun 21;7(25):38257-38269

[12]Meng Jie, Fangqin Guo, Haiyan Xu, WeiLiang, Chen Wang, Xian-Da Yang
Combination Therapy using Co-encapsulated Resveratrol and Paclitaxelin
Liposomes for Drug Resistance Reversal in Breast Cancer Cells in
Vivo (2016) 6:1-11

近年获得专利：
1. HER2蛋白核酸适配子、复合体、组合物及其用途（专利号：3.9）
2. MUC1蛋白核酸适配子、复合体、组合物及其用途（专利号：9.8）